 AUSTIN, TX and DURHAM, NC, Dec. 18, 2020 GLOBE NEWSWIRE -- Shattuck Labs, Inc. Shattuck NASDAQ: STTK, a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will be added to the Russell 2000 and 3000 Indexes effective December 21, 2020, following Russells quarterly additions of select initial public offerings. 